Stocks of ProNAi Therapeutics (NASDAQ:DNAI) rallied by 5.03% during the past week but lost 64.09% on a 4-week basis. The company has outperformed the S&P 500 by 6.29% in the past week but underperformed the index by 64.42% in the last 4 weeks.
ProNAi Therapeutics (NASDAQ:DNAI): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.08 and $2.06 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.16. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.09, notching a gain of 1.46% for the day. The total traded volume was 1,796,227 . The stock had closed at $2.06 on the previous day.
On the companys insider trading activities, The officer (SVP Clinical Operations), of Pronai Therapeutics Inc, Chapman Wendy had unloaded 3,000 shares at $7.01 per share in a transaction on March 22, 2016. The total value of transaction was $21,030. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Many analysts have stated their opinion on the company shares. Jefferies downgrades their rating on the shares of ProNAi Therapeutics (NASDAQ:DNAI). The current rating of the shares is Hold. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on June 6, 2016. Institutional Investors own 65.1% of ProNAi Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -9.21%.
ProNAi Therapeutics, Inc. is a clinical-stage oncology company. The Company develops and commercializes a portfolio of therapeutics based on its deoxyribonucleic acid interference (DNAi) technology platform for patients with cancer and hematological diseases. The Companys lead DNAi product candidate, PNT2258, treat cancers that overexpress BCL2, an oncogene known to be dysregulated in many types of cancer. Its platform consists of two components: Rationally-Designed DNAi Oligonucleotides and Lipid Nanoparticle (LNP) Delivery Technology. The Company has conducted two clinical trials for PNT2258: a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkins lymphoma (NHL). It has initiated Wolverine, a Phase II trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.